Search IconSearch
March 4, 2020/COVID-19

Coronaviruses Have Been Around For Centuries: What Differentiates COVID-19?

What to know about transmission, who is at risk and how to protect your patients


To better understand the SARS-CoV-2 virus and COVID-19, the disease it causes, from an infectious disease perspective, some experts advise viewing coronaviruses categorically as “old” and “new” in terms of how long these viruses have been infecting humans.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Frank Esper, MD, a pediatric infectious disease specialist at Cleveland Clinic, notes that genetically they are separated into four groups: alpha, beta, gamma and delta coronaviruses; only alpha and beta coronaviruses have been found to infect humans.1

The older human coronaviruses were first identified in the mid-1960s, but have likely circulated in humans for centuries. These include 229E (alpha coronavirus), NL63 (alpha coronavirus), OC43 (beta coronavirus) and HKU1 (beta coronavirus).2 For the most part, these older iterations present with a mild respiratory infection, except for HKU1, which can also cause gastrointestinal infection, he notes.

Dr. Esper refers to the newer coronaviruses as “true emerging infectious diseases.” These include SARS-CoV (SARS), MERS-CoV (MERS) and, of course, SARS-CoV-2. He explains, “These are strains that have undergone recent animal-to-human transition.” This can happen when a virus either mutates directly to humans, or through a second (intermediary) species that then further mutates into a human pathogen.

“This is what we saw with SARS in 2002-2003 and MERS in 2012 and likely what just happened with SARS-CoV-2,” he says.

For the most part, these viral mutations occur in animals — and predominantly stay in animals — but when the rare mutation allows transmission into humans, our immune systems are less-equipped to manage the disease. “This is the case with these larger epidemics we have seen; although, it’s important to remember, just because a mutation is demonstrating human transmission, doesn’t mean it’s reproducing well,” he says.


In cases of MERS, SARS and SARS-CoV-2, reproduction was successful enough to jump from animal-to-human and then from human-to-human, but that doesn’t mean it has evolved enough to become a persistent human pathogen.

“Once these virus mutations allow transmission to humans, their survival becomes dependent on optimization of virus infection between humans.” A swift public health response can mitigate the likelihood of this by limiting the spread of infection in humans and, thus, reducing the chance of new, more efficient viruses from emerging. In some cases, unpredictable variables may also work to suppress the spread of the virus, like weather conditions or other circulating pathogens, as examples.

“We are still speculating why exactly SARS disappeared. One hypothesis is that while SARS was able to cause human-to-human transmission, the virus wasn’t able to go from one season to the next. It basically got its one winter transmission season then largely disappeared and never came back.”

To put the more modern coronaviruses in perspective, the case-fatality rate for SARS was 9.6%; the virus infected a total of 8,098 individuals during the 2003 outbreak and 774 of these cases were fatal.3 Unlike SARS, the MERS outbreak of 2012 continues to infect several dozen patients each year. The World Health Organization reports that since Sept. 2012, there have been a total of 2,494 confirmed cases and 858 fatalities, a case-fatality rate of 34.4%.4

The virulence of SARS-Cov-2 remains to be seen, although it has demonstrated significant adaptability to spread from person-to-person in areas of outbreak and outpaced SARS in number of documented cases and fatalities. Dr. Esper cautions that the true number of infected patients will still take some time to confirm.

Globalization and the ‘new’ coronaviruses

The “new” coronaviruses have also taught us a lot about infectious disease in an era of globalization.

It’s been almost 20 years since the SARS outbreak occurred. Dr. Esper stresses that this was a moment in infectious disease history that highlighted the implications of a pandemic in an era of increased global connectivity, for better and for worse.

“It was a wake-up call. We saw the virus’s ability to circulate very quickly across countries and into new global regions. On the other hand, we also saw a substantial collaborative response among countries and regions to halt and prevent the spread.”

The World Health Organization developed a global outbreak alert and response network shortly after the SARS outbreak. They have continued to strengthen these efforts to equip clinicians with tools and resources to manage patient care and provide real-time data and safety alerts to the public.

“It does stand to reason, however, that we are not playing catch-up as much with this virus as we were with the previous SARS and MERS coronaviruses or pandemic influenza, where by the time we recognized there was a new strain of the virus, it already spread elsewhere in the world.”


What’s next?

There is currently no vaccine for COVID-19, although development efforts are underway. Dr. Esper notes that making a vaccine is only a fraction of the job. “You have to make sure that the vaccine is safe, effective and can be stably transported to people who need it, not just in one country but across the world,” he says. “Growing the virus to develop a viable vaccine candidate is an important step, but there are still many others.”

In the U.S, a clinical trial is investigating the use of remdesivir, a broad-spectrum antiviral drug, to treat COVID-19, but so far there are no data to validate its efficacy to treat this particular strain of the disease.

This rapidly evolving situation means clinicians should remain vigilant and up-to-date on public health guidelines, keeping in mind that there is still much more we are going to learn about this virus.

“At this point in time, there is no treatment. There is no vaccine. The best thing we can do is give everyone the information that they need on how to protect themselves, which will also aid in mitigating further spread,” says Dr. Esper.


  1. Cui J, Li F, Shi ZL. Nat Rev Microbiol. 2019 Mar;17(3):181-192.
  2. Human Coronavirus Types. https://www.cdc.gov/coronavirus/types.html. Accessed March 5, 2020.
  3. Centers for Disease Control and Prevention. https://www.cdc.gov/sars/about/fs-sars.html. Published December 6, 2017. Accessed February 7, 2020.
  4. Middle East respiratory syndrome coronavirus (MERS-CoV). World Health Organization. https://www.who.int/emergencies/mers-cov/en/. Published January 23, 2020. Accessed February 7, 2020.


Related Articles

Stellate Ganglion Block
May 17, 2023/COVID-19
Nerve Block Shows Promise for Long COVID-Related Olfactory or Gustatory Dysfunction

Patients report improved sense of smell and taste

Covid image
April 26, 2023/COVID-19
What Long COVID Means for Rheumatologists (Video)

Clinicians who are accustomed to uncertainty can do well by patients

Covid related skin effects
April 4, 2023/COVID-19
Cutaneous Manifestations of COVID-19 in Special Populations

Unique skin changes can occur after infection or vaccine

February 10, 2023/COVID-19
Effects of COVID-19 on Blood Sugar and Type 2 Diabetes

Cleveland Clinic analysis suggests that obtaining care for the virus might reveal a previously undiagnosed condition

January 13, 2023/COVID-19
Optimal Management of High Risk Immunocompromised Patients in the COVID-19 Era

As the pandemic evolves, rheumatologists must continue to be mindful of most vulnerable patients

covid-19 virus
January 12, 2023/COVID-19
Real World Experience with Tixagevimab/Cilgavimab in B-Cell-Depleted Patients

Early results suggest positive outcomes from COVID-19 PrEP treatment

Eosinophilic Fasciitis
November 29, 2022/COVID-19
New Onset Eosinophilic Fasciitis after COVID-19 Infection

Could the virus have caused the condition or triggered previously undiagnosed disease?

COVID-19 and rash
June 16, 2022/COVID-19
Common Skin Signs of COVID-19 in Adults: An Update

Five categories of cutaneous abnormalities are associated with COVID-19